Ultra-long-acting insulin degludec has a unique pharmacokinetic profile compared to insulin glargine. The reason for its prolonged and flat action profile (>42 hours) is:

• A Precipitation at the acid pH of the subcutaneous depot, forming insoluble crystals that dissolve slowly
• B Attachment of a polyethylene glycol (PEG) polymer that prevents renal filtration and reduces hepatic uptake
• C Incorporation into liposomal nanoparticles within the subcutaneous depot that slowly release insulin over days
• D Formation of soluble multi-hexameric chains (dihexameric depots) that release monomers slowly; enhanced albumin binding via the C18 fatty diacid chain prolongs vascular transit ✓

Explanation

Insulin degludec contains a C18 fatty diacid chain (hexadecandioic acid) attached via a gamma-glutamic acid linker. At the subcutaneous injection site it self-assembles into large soluble multi-hexameric complexes (di-hexamers forming chains); these slowly shed monomers. The shed monomers bind reversibly to albumin in plasma via the fatty acid chain, further buffering distribution and prolonging action. This dual depot-albumin binding mechanism produces an extremely flat (peakless) action profile lasting over 42 hours. Glargine precipitates due to acidic pH (pH 4) — a different mechanism. PEGylation and liposomes are not features of commercial insulins.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.